Skin-resident antigen-presenting cells: Instruction manual for vaccine development

Frontiers in Immunology

Volumn 4, Issue JUN, 2013, Pages

  Fehres, Cynthia M ^a   Garcia Vallejo, Juan J ^a   Unger, Wendy W J ^a   van Kooyk, Yvette ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antigen presenting cells; C type lectin receptors; Glycans; Microneedles; Skin; Vaccination

Indexed keywords

CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; LANGERIN; LECTIN RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; VACCINE;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; DENDRITIC CELL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KERATINOCYTE; LYMPH NODE; MICRONEEDLE; NONHUMAN; REVIEW; VACCINATION;

EID: 84883806063     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00157     Document Type: Review

References (55)

1. Alving, C. R., Peachman, K. K., Rao, M., and Reed, S. G. (2012). Adjuvants for human vaccines. Curr. Opin. Immunol. 24, 310-315. doi:10.1016/j.coi.2012.03.008
2. Angel, C. E., Lala, A., Chen, C.-J. J., Edgar, S. G., Ostrovsky, L. L., and Dunbar, P. R. (2007). CD14+ antigen-presenting cells in human dermis are less mature than their CD1a+ counterparts. Int. Immunol. 19, 1271-1279. doi:10.1093/intimm/dxm096
3. Bachy, V., Hervouet, C., Becker, P. D., Chorro, L., Carlin, L. M., Herath, S., et al. (2013). Langerin negative dendritic cells promote potent CD8+ T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays. Proc. Natl. Acad. Sci. U.S.A. 110, 3041-3046. doi:10.1073/pnas.1214449110
4. Banchereau, J., Thompson-Snipes, L., Zurawski, S., Blanck, J.-P., Cao, Y., Clayton, S., et al. (2012). The differential production of cytokines by human Langerhans cells and dermal CD14(+) DCs controls CTL priming. Blood 119, 5742-5749. doi:10.1182/blood-2011-08-371245
5. Begon, E., Michel, L., Flageul, B., Beaudoin, I., Jean-Louis, F., Bachelez, H., et al. (2007). Expression, subcellular localization and cytokinic modulation of Toll-like receptors (TLRs) in normal human keratinocytes: TLR2 up-regulation in psoriatic skin. Eur. J. Dermatol. 17, 497-506.
6. Bobr, A., Igyarto, B. Z., Haley, K. M., Li, M. O., Flavell, R. A., and Kaplan, D. H. (2012). Autocrine/paracrine TGF-β1 inhibits Langerhans cell migration. Proc. Natl. Acad. Sci. U.S.A. 109, 10492-10497. doi:10.1073/pnas.1119178109
7. Bonifaz, L., Bonnyay, D., Mahnke, K., Rivera, M., Nussenzweig, M. C., and Steinman, R. M. (2002). Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 196, 1627-1638. doi:10.1084/jem.20021598
8. Bonifaz, L. C., Bonnyay, D. P., Charalambous, A., Darguste, D. I., Fujii, S.-I., Soares, H., et al. (2004). In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199, 815-824. doi:10.1084/jem.20032220
9. Bystrova, S., and Luttge, R. (2011). Micromolding for ceramic microneedle arrays. Microelectron. Eng. 88, 1681-1684. doi:10.1016/j.mee.2010.12.067
10. Caminschi, I., Proietto, A. I., Ahmet, F., Kitsoulis, S., Shin Teh, J., Lo, J. C. Y., et al. (2008). The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood 112, 3264-3273. doi:10.1182/blood-2008-05-155176
11. Caminschi, I., and Shortman, K. (2012). Boosting antibody responses by targeting antigens to dendritic cells. Trends Immunol. 33, 71-77. doi:10.1016/j.it.2011.10.007
12. de Witte, M. A., Bendle, G. M., van den Boom, M. D., Coccoris, M., Schell, T. D., Tevethia, S. S., et al. (2008a). TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J. Immunol. 181, 2563-2571.
13. de Witte, M. A., Jorritsma, A., Kaiser, A., van den Boom, M. D., Dokter, M., Bendle, G. M., et al. (2008b). Requirements for effective antitumor responses of TCR transduced T cells. J. Immunol. 181, 5128-5136.
14. del Pilar Martin, M., Weldon, W. C., Zarnitsyn, V. G., Koutsonanos, D. G., Akbari, H., Skountzou, I., et al. (2012). Local response to microneedle-based influenza immunization in the skin. MBio 3, e00012. doi:10.1128/mBio.00012-12
15. Fenoglio, D., Traverso, P., Parodi, A., Tomasello, L., Negrini, S., Kalli, F., et al. (2013). A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. Cancer Immunol. Immunother. 62, 1041-1052. doi:10.1007/s00262-013-1415-9
16. Flisiak, I., Chodynicka, B., Porebski, P., and Flisiak, R. (2002). Association between psoriasis severity and transforming growth factor beta(1) and beta (2) in plasma and scales from psoriatic lesions. Cytokine 19, 121-125. doi:10.1006/cyto.2002.1953
17. Flisiak, I., Porebski, P., Flisiak, R., and Chodynicka, B. (2003). Plasma transforming growth factor beta1 as a biomarker of psoriasis activity and treatment efficacy. Biomarkers 8, 437-443. doi:10.1080/13547500310001599061
18. Galluzzi, L., Senovilla, L., Vacchelli, E., Eggermont, A., Fridman, W. H., Galon, J., et al. (2012). Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 1, 1111-1134. doi:10.4161/onci.21494
19. Gattinoni, L., Klebanoff, C. A., Palmer, D. C., Wrzesinski, C., Kerstann, K., Yu, Z., et al. (2005). Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115, 1616-1626. doi:10.1172/JCI24480
20. Gattinoni, L., Klebanoff, C. A., and Restifo, N. P. (2012). Paths to stemness: building the ultimate antitumour T cell. Nat. Rev. Cancer 12, 671-684. doi:10.1038/nrc3322
21. Grotz, T. E., Kottschade, L., Pavey, E. S., Markovic, S. N., and Jakub, J. W. (2013). Adjuvant GM-CSF improves survival in high-risk stage IIIC melanoma: a single-center study. Am. J. Clin. Oncol. (in press).
22. Haniffa, M., Shin, A., Bigley, V., McGovern, N., Teo, P., See, P., et al. (2012). Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity 37, 60-73. doi:10.1016/j.immuni
23. Hémont, C., Neel, A., Heslan, M., Braudeau, C., and Josien, R. (2013). Human blood mDC subsets exhibit distinct TLR repertoire and responsiveness. J. Leukoc. Biol. 93, 599-609. doi:10.1189/jlb.0912452
24. Holla, A., and Skerra, A. (2011). Comparative analysis reveals selective recognition of glycans by the dendritic cell receptors DC-SIGN and Langerin. Protein Eng. Des. Sel. 24, 659-669. doi:10.1093/protein/gzr016
25. Kenney, R. T., Frech, S. A., Muenz, L. R., Villar, C. P., and Glenn, G. M. (2004). Dose sparing with intradermal injection of influenza vaccine. N. Engl. J. Med. 351, 2295-2301. doi:10.1056/NEJMoa043540
26. Klebanoff, C. A., Gattinoni, L., Palmer, D. C., Muranski, P., Ji, Y., Hinrichs, C. S., et al. (2011). Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin. Cancer Res. 17, 5343-5352. doi:10.1158/1078-0432.CCR-11-0503
27. Klebanoff, C. A., Yu, Z., Hwang, L. N., Palmer, D. C., Gattinoni, L., and Restifo, N. P. (2009). Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination. Blood 114, 1776-1783. doi:10.1182/blood-2008-12-192419
28. Klechevsky, E., Liu, M., Morita, R., Banchereau, R., Thompson-Snipes, L., Palucka, A. K., et al. (2009). Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines. Hum. Immunol. 70, 281-288. doi:10.1016/j.humimm.2009.02.004
29. Klechevsky, E., Morita, R., Liu, M., Cao, Y., Coquery, S., Thompson-Snipes, L., et al. (2008). Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 29, 497-510. doi:10.1016/j.immuni
30. Koutsonanos, D. G., del Pilar Martin, M., Zarnitsyn, V. G., Jacob, J., Prausnitz, M. R., Compans, R. W., et al. (2011). Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination. J. Infect. Dis. 204, 582-591. doi:10.1093/infdis/jir094
31. Lebre, M. C., van der Aar, A. M. G., van Baarsen, L., van Capel, T. M. M., Schuitemaker, J. H. N., Kapsenberg, M. L., et al. (2007). Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J. Invest. Dermatol. 127, 331-341. doi:10.1038/sj.jid.5700530
32. Lee, R. T., Hsu, T.-L., Huang, S.-K., Hsieh, S.-L., Wong, C.-H., and Lee, Y. C. (2011). Survey of immune-related, mannose/fucose-binding C-type lectin receptors reveals widely divergent sugar-binding specificities. Glycobiology 21, 512-520. doi:10.1093/glycob/cwq193
33. Maldonado, R. A., and von Andrian, U. H. (2010). How tolerogenic dendritic cells induce regulatory T cells. Adv. Immunol. 108, 111-165. doi:10.1016/B978-0-12-380995-7.00004-5
34. Meixlsperger, S., Leung, C. S., Rämer, P. C., Pack, M., Vanoaica, L. D., Breton, G., et al. (2013). CD141+ dendritic cells produce prominent amounts of IFN-α after dsRNA recognition and can be targeted via DEC-205 in humanized mice. Blood (in press). doi:10.1182/blood-2012-12-473413
35. Oosterhoff, D., Heusinkveld, M., Lougheed, S. M., Kosten, I., Lindstedt, M., Bruijns, S. C. M., et al. (2013). Intradermal delivery of TLR agonists in a human explant skin model: preferential activation of migratory dendritic cells by polyribosinic-polyribocytidylic acid and peptidoglycans. J. Immunol. 190, 3338-3345. doi:10.4049/jimmunol.1200598
36. Overwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth-Dreese, F. A., et al. (2003). Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569-580. doi:10.1084/jem.20030590
37. Poulin, L. F., Salio, M., Griessinger, E., Anjos-Afonso, F., Craciun, L., Chen, J.-L., et al. (2010). Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J. Exp. Med. 207, 1261-1271. doi:10.1084/jem.20092618
38. Restifo, N. P., Dudley, M. E., and Rosenberg, S. A. (2012). Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12, 269-281. doi:10.1038/nri3191
39. Schneider, L. P., Schoonderwoerd, A. J., Moutaftsi, M., Howard, R. F., Reed, S. G., de Jong, E. C., et al. (2012). Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells. Vaccine 30, 4216-4224. doi:10.1016/j.vaccine.2012.04.051
40. Segura, E., Valladeau-Guilemond, J., Donnadieu, M.-H., Sastre-Garau, X., Soumelis, V., and Amigorena, S. (2012). Characterization of resident and migratory dendritic cells in human lymph nodes. J. Exp. Med. 209, 653-660. doi:10.1084/jem.20111457
41. Sullivan, S. P., Koutsonanos, D. G., del Pilar Martin, M., Lee, J. W., Zarnitsyn, V., Choi, S.-O., et al. (2010). Dissolving polymer microneedle patches for influenza vaccination. Nat. Med. 16, 915-920. doi:10.1038/nm.2182
42. Tacken, P. J., de Vries, I. J. M., Torensma, R., and Figdor, C. G. (2007). Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7, 790-802. doi:10.1038/nri2173
43. Tel, J., Schreibelt, G., Sittig, S. P., Mathan, T. S. M., Buschow, S. I., Cruz, L. J., et al. (2013). Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood 121, 459-467. doi:10.1182/blood-2012-06-435644
44. Tel, J., Smits, E. L., Anguille, S., Joshi, R. N., Figdor, C. G., and de Vries, I. J. M. (2012). Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood 120, 3936-3944. doi:10.1182/blood-2012-06-435941
45. Turtle, C. J., Hudecek, M., Jensen, M. C., and Riddell, S. R. (2012). Engineered T cells for anti-cancer therapy. Curr. Opin. Immunol. 24, 633-639. doi:10.1016/j.coi.2012.06.004
46. Ueno, H., Klechevsky, E., Morita, R., Aspord, C., Cao, T., Matsui, T., et al. (2007). Dendritic cell subsets in health and disease. Immunol. Rev. 219, 118-142. doi:10.1111/j.1600-065X.2007.00551.x
47. Unger, W. W. J., van Beelen, A. J., Bruijns, S. C., Joshi, M., Fehres, C. M., van Bloois, L., et al. (2012). Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells. J. Control. Release 160, 88-95. doi:10.1016/j.jconrel.2012.02.007
48. Unger, W. W. J., and van Kooyk, Y. (2011). Dressed for success. Curr. Opin. Immunol. 23, 131-137. doi:10.1016/j.coi.2010.11.011
49. van de Ven, R., van den Hout, M. F. C. M., Lindenberg, J. J., Sluijter, B. J. R., van Leeuwen, P. A. M., Lougheed, S. M., et al. (2011). Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation. Blood 118, 2502-2510. doi:10.1182/blood-2011-03-344838
50. van den Eertwegh, A. J., Versluis, J., van den Berg, H. P., Santegoets, S. J., van Moorselaar, R. J. A., van der Sluis, T. M., et al. (2012). Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 13, 509-517. doi:10.1016/S1470-2045(12)70007-4
51. van der Aar, A. M. G., Sylva-Steenland, R. M. R., Bos, J. D., Kapsenberg, M. L., de Jong, E. C., and Teunissen, M. B. M. (2007). Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J. Immunol. 178, 1986-1990.
52. van der Maaden, K., Jiskoot, W., and Bouwstra, J. (2012). Microneedle technologies for (trans)dermal drug and vaccine delivery. J. Control. Release 161, 645-655. doi:10.1016/j.jconrel.2012.01.042
53. Wang, X.-J., Han, G., Owens, P., Siddiqui, Y., and Li, A. G. (2006). Role of TGF beta-mediated inflammation in cutaneous wound healing. J. Investig. Dermatol. Symp. Proc. 11, 112-117. doi:10.1038/sj.jidsymp.5650004
54. Zaric, M., Lyubomska, O., Touzelet, O., Poux, C., Al-Zahrani, S., Fay, F., et al. (2013). Skin dendritic cell targeting via microneedle arrays laden with antigen-encapsulated poly-d, l-lactide-co-glycolide nanoparticles induces efficient antitumor and antiviral immune responses. ACS Nano 7, 2042-2055. doi:10.1021/nn304235j
55. Zuber, A. K., Bråve, A., Engström, G., Zuber, B., Ljungberg, K., Fredriksson, M., et al. (2004). Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA. Vaccine 22, 1791-1798. doi:10.1016/j.vaccine.2003.10.051